REKRUZIQ Trademark

Trademark Overview

On Monday, April 11, 2022, a trademark application was filed for REKRUZIQ with the United States Patent and Trademark Office. The USPTO has given the REKRUZIQ trademark a serial number of 97357525. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, March 27, 2025. This trademark is owned by Checkpoint Therapeutics, Inc.. The REKRUZIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the treatment of cancer
rekruziq

General Information

Serial Number97357525
Word MarkREKRUZIQ
Filing DateMonday, April 11, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, March 27, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 7, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCheckpoint Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02453
Party NameCheckpoint Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02453

Trademark Events

Event DateEvent Description
Friday, January 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 14, 2022NEW APPLICATION ENTERED
Monday, April 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 27, 2023ASSIGNED TO EXAMINER
Tuesday, March 7, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 7, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 2, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 15, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 15, 2023SOU EXTENSION 1 FILED
Tuesday, August 15, 2023SOU EXTENSION 1 GRANTED
Thursday, August 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 5, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 5, 2024SOU EXTENSION 2 FILED
Monday, February 5, 2024SOU EXTENSION 2 GRANTED
Monday, August 5, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, February 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 5, 2024SOU EXTENSION 3 GRANTED
Monday, August 5, 2024SOU EXTENSION 3 FILED
Thursday, March 27, 2025SOU TEAS EXTENSION RECEIVED
Thursday, March 27, 2025SOU EXTENSION 4 FILED
Thursday, March 27, 2025SOU EXTENSION 4 GRANTED
Thursday, March 27, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

rekruziq cancer treatment preparations pharmaceutical